The financing comes after the company raised $30 million in August.
Iterative Scopes will focus on inflammatory bowel disease and colorectal cancer prevention with the development of its AI technology products and services.
The company offers an automated polyp detection tool, endoscopic scoring systems and a recruitment service for pharmaceutical companies to accelerate their IBD clinical trials.
